Although a glutaminyl cyclase inhibitor discovered by Probiodrug and shown to be safe and well tolerated in a Phase I clinical trial, is now in further clinical development for the treatment of AD, this strategy has a drawback of inhibiting an enzyme with a key function in the posttranslational processing of several hormones, converting amino-terminal glutamine into pyroGlu. Here, QPCT is linked to Alzheimer disease.